MTFP1 and Metabolic Reprogramming: Unlocking New Targets in Pancreatic Cancer Liver Metastasis
Highlight
– MTFP1 identified as a key driver of pancreatic ductal adenocarcinoma (PDAC) liver metastasis via regulation of mitochondrial oxidative phosphorylation.
– MTFP1 interacts with ATP synthase subunits, enhancing oxidative phosphorylation and increasing mitochondrial fission.
– Upregulated reactive oxygen species (ROS) trigger the PI3K/AKT/c-MYC/SLC1A5 pathway, promoting glutamine uptake that supports tumor growth and suppresses CD8+ T-cell antitumor responses.
– Inhibition of MTFP1 or limiting glutamine uptake reverses the immunosuppressive tumor microenvironment (TME) and reduces liver colonization in PDAC.
– Identification of KPT 9274 (ATG-019) as a potential MTFP1 inhibitor offers a novel therapeutic avenue for PDAC patients with liver metastases.
Study Background
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.